J. Antal

R. Bukowski, G. Budd, M. Thomassen, 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Regulation of human alveolar macrophage inflammatory cytokines by tyloxapol: a component of the synthetic surfactant Exosurf.

H. Wiedemann, M. Thomassen, J. Antal, 1995, Clinical immunology and immunopathology.

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study

Nicholas J. Vogelzang, Jingsong Zhang, Michael Ong, 2017, JAMA oncology.

Trilaciclib (trila) preserves and enhances immune system function in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy.

T. Owonikoko, K. Dragnev, J. Sorrentino, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study

J. Subramanian, T. Owonikoko, L. Hart, 2020, Advances in Therapy.

Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma.

M. Rebelatto, C. Sabalos, A. Gupta, 2018, Archives of pathology & laboratory medicine.

Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled Phase II trial

I. Bondarenko, L. Hart, J. Goldschmidt, 2020, International journal of cancer.

Clinical Activity, Tolerability, and Long-term Follow-up of Durvalumab in Patients With Advanced NSCLC.

D. Jäger, P. Ascierto, J. Nemunaitis, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma.

T. Powles, M. Fishman, S. Srinivas, 2017 .

Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies

Y. Pritchett, A. Spira, J. Beck, 2021, Cancer management and research.

Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.

C. Gwaltney, K. Dragnev, K. Skaltsa, 2021, Clinical lung cancer.

Amyloid β and Amylin Fibrils Induce Increases in Proinflammatory Cytokine and Chemokine Production by THP‐1 Cells and Murine Microglia

S. L. Yates, K. Brunden, L. H. Burgess, 2000, Journal of neurochemistry.

Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC).

J. Nemunaitis, J. Marshall, R. Finn, 2017 .

Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC).

M. Kudo, A. Zhu, G. Abou-Alfa, 2016 .